TRIM33 and cancer: For example, patients with dermatomyositis and antibodies against transcription intermediary factor 1-gamma (TIF1γ) or nuclear matrix protein 2 (NXP2) have an increased risk of cancer-associated myositis [2], and in systemic sclerosis (scleroderma), patients with anti-RNA polymerase III (POLR3) antibodies have a higher risk of cancer-associated scleroderma [3–5].